CEL-SCI Corp, Cell Med Inc deal

CELI acquired Cell Med's T cell Modulation Process, which uses heteroconjugates to direct the body to choose a specific immune response. CELI plans to use the process to improve the cellular immune responses of its HIV HGP-30 immunogen, which is in clinical trials. CELI also will continue Cell Med's development of a tuberculosis vaccine/treatment which is in preclinical development. ...